Clinical trials: Connective Tissue Defect
- Condition Connective Tissue Defect
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Osteoarthritis, Avascular Necrosis
Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction
The study is a multi-center, prospective, non-controlled, consecutive cohort post market surveillance study. The objective of this study is to obtain survival and clinical outcome data on the Hyperion® system in primary and…
- Conditions
- Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Functional Deformities
- Trial name
- NCT03382665
- Where
- 3 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Zimmer Biomet
Connective Tissue Defect
Post-Market Clinical Follow Up Study to Collect Additional Data and Imaging
This is a prospective, open label, multi-center clinical study to collect additional data and imaging for the ViaSure device.The intended use of the ViaSure device used in this study is to assess the usability and tissue response…
- Trial name
- NCT04880070
- Testing
- Shockwave Treatment
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cynosure, Inc.
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Dermatitis, Atopic
A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Atopic dermatitis (AD) is among the most common chronic types of inflammatory skin disease and it is characterised by exacerbations or relapses over years.
- Trial name
- NCT03901144
- Testing
- 2% urea/20% glycerol cream, Miniderm® 20% cream, Diprobase® cream
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- ACO Hud Nordic AB